Bayer’s (BAYRY) wholly owned and independently operated subsidiary, Vividion Therapeutics, Inc, announced that the first patient has been dosed in a phase I study evaluating VVD-159642.VVD-159642 is an investigational oral inhibitor designed to target RAS-driven cancers.The phase I study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of VVD-159642 as a single agent and in combination with either Lumakras (sotorasib) or trametinib in patients wi ...